Advertisement ActivBiotics sells intellectual property assets for $3.5 million - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ActivBiotics sells intellectual property assets for $3.5 million

Joseph Finn, Jr., the assignee for the benefit of creditors of ActivBiotics, has announced the completion of the sale of company's intellectual property assets for $3.5 million.

The assets consisted of, rifalazil, a Phase II antibiotic, a library of novel rifamycin compounds, and a clinical stage superoxide dismutase mimetic (SODm) and a library of SODm small molecules.

The sale of the assets was conducted through an assignment for the benefit of creditors. This process entails transference of the assets to a fiduciary who then liquidates them for the benefit of the creditors of the company.